Dexamethasone Modulates Lipoprotein Metabolism in Cultured Human Monocyte-derived Macrophages. Stimulation of Scavenger Receptor Activity
Overview
Authors
Affiliations
Human monocyte-derived macrophages (HMM) play a key role in the formation of atherosclerotic plaques by accumulating cholesteryl ester (CE) to become foam cells. HMM have receptors for native low density lipoprotein (LDL) and acetylated-LDL (ALDL), and uptake of ALDL can promote substantial cellular CE accumulation. Furthermore, macrophages specifically and saturably bind glucocorticoids, which in turn modulate numerous macrophage functions. Preincubating HMM in dexamethasone-inhibited LDL degradation (230 +/- 12 vs. 515 +/- 21 ng/mg cell protein X 18 h, P less than 0.001) but stimulated ALDL degradation (5.3 +/- 0.5 vs. 2.5 +/- 0.3 micrograms/mg X 18 h, P less than 0.01). These effects were time- and dose-dependent, occurring maximally by 24 h and with 2.5 X 10(-8) M dexamethasone. Dexamethasone increased the maximum velocity for ALDL degradation (16.2 vs. 12.0 micrograms/mg X 18 h, P less than 0.01) without changing the apparent Michaelis constant. Progesterone, 11 alpha-epicortisol, and 17 alpha-OH progesterone (a competitive antagonist of the glucocorticoid receptor) had no effect on HMM ALDL degradation, but 17 alpha-OH progesterone abolished the stimulatory action of dexamethasone. In he presence of ALDL, incorporation of [14C]oleic acid into CE was enhanced over fourfold by dexamethasone (4015 +/- 586 vs. 943 +/- 91 cpm/mg X 2 h, P less than 0.01), and HMM incubated with ALDL and dexamethasone accumulated more free cholesterol (34.6 +/- 1.9 vs. 26.2 +/- 0.8 micrograms/mg, P less than 0.02) and CE (32.8 +/- 2.3 vs. 14.8 +/- 0.8 micrograms/mg, P less than 0.002) than did macrophages without dexamethasone. In cultured human umbilical vein endothelial cells, dexamethasone did not change ALDL degradation, but reduced LDL degradation by 30% (P less than 0.001). In summary, dexamethasone inhibits LDL receptor activity by both macrophages and endothelial cells, but stimulates ALDL receptor activity only in macrophages. These observations provide evidence for the regulation of macrophage endocytic receptors by glucocorticoid hormones.
Zhu J, Hong L, Yuan S, Xu X, Wei J, Yin H Front Pharmacol. 2023; 14:1118551.
PMID: 36713831 PMC: 9877223. DOI: 10.3389/fphar.2023.1118551.
Ospina-Quintero L, Jaramillo J, Tabares-Guevara J, Ramirez-Pineda J Front Immunol. 2020; 11:743.
PMID: 32395119 PMC: 7197409. DOI: 10.3389/fimmu.2020.00743.
Lau K, Tancredi D, Perez R, Butani L Clin J Am Soc Nephrol. 2010; 5(8):1506-12.
PMID: 20507961 PMC: 2924403. DOI: 10.2215/CJN.08431109.
Antioxidant: a new role for RU-486 and related compounds.
Parthasarathy S, Morales A, Murphy A J Clin Invest. 1994; 94(5):1990-5.
PMID: 7962545 PMC: 294624. DOI: 10.1172/JCI117551.
Lechleitner M, Auer B, Zilian U, Hoppichler F, Schirmer M, Foger B Lipids. 1994; 29(9):627-33.
PMID: 7815897 DOI: 10.1007/BF02536097.